Reshape Lifesciences Inc has a consensus price target of $6.33, established from looking at the 2 latest analyst ratings. The last 2 analyst ratings were released from Alliance Global Partners and Maxim Group on May 26, 2022 and October 8, 2021. With an average price target of $6.33 between Alliance Global Partners and Maxim Group, there's an implied 3551.85% upside for Reshape Lifesciences Inc from these 2 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
05/26/2022 | RSLS | Buy Now | Reshape Lifesciences | $0.17 | 2584.76% | Alliance Global Partners | Ben Haynor | $275 → $232.5 | Maintains | Buy | Get Alert |
10/08/2021 | RSLS | Buy Now | Reshape Lifesciences | $0.17 | 4518.94% | Maxim Group | Anthony Vendetti | — | Initiates | → Buy | Get Alert |
The latest price target for Reshape Lifesciences (NASDAQ: RSLS) was reported by Alliance Global Partners on May 26, 2022. The analyst firm set a price target for $4.65 expecting RSLS to rise to within 12 months (a possible 2584.76% upside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for Reshape Lifesciences (NASDAQ: RSLS) was provided by Alliance Global Partners, and Reshape Lifesciences maintained their buy rating.
There is no last upgrade for Reshape Lifesciences.
There is no last downgrade for Reshape Lifesciences.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reshape Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reshape Lifesciences was filed on May 26, 2022 so you should expect the next rating to be made available sometime around May 26, 2023.
While ratings are subjective and will change, the latest Reshape Lifesciences (RSLS) rating was a maintained with a price target of $5.50 to $4.65. The current price Reshape Lifesciences (RSLS) is trading at is $0.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.